LXRX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LX

Mkt Cap

$678.6M

Volume

1.71M

Next Earnings

November 5th

Loading chart

LX

LXRXLexicon Pharmaceuticals, Inc.

LXRX

Pay with—

Available Balance0.00

LX

Mkt Cap

$734.2M

Volume

1.71M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% TodayLexicon Pharmaceuticals stock surged nearly 6% after analyst Steve Seedhouse from Cantor Fitzgerald initiated coverage with an 'overweight' rating and $8 price target (over 4x the current $1.90 price). Seedhouse highlighted the company's progress on sotagliflozin, an FDA-approved heart failure drug being developed for hypertrophic cardiomyopathy, which works through a different mechanism than competing treatments.The Motley Fool · Sep 28, 2026

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsLexicon Pharmaceuticals announced it will present clinical study data on sotagliflozin for Type 1 diabetes and pilavapadin for diabetic peripheral neuropathic pain at the American Diabetes Association 2026 Scientific Sessions in New Orleans. The company highlighted consistent A1c reductions with sotagliflozin across patient subgroups and pharmacokinetic data for pilavapadin. An NDA resubmission for sotagliflozin in T1D is on track for mid-year 2026.GlobeNewswire Inc. · Jun 3, 2026

Navigating Life with Hypertrophic CardiomyopathyHypertrophic cardiomyopathy (HCM) is a complex genetic heart condition causing thickening and stiffening of the heart muscle, leading to symptoms like fatigue, breathlessness, and chest discomfort. The condition can develop at any age and carries risks of serious complications including heart failure and sudden death. While no medications currently prevent HCM, treatments for obstructive HCM may include cardiac myosin inhibitors. Lexicon Pharmaceuticals is conducting the SONATA-HCM clinical trial to investigate sotagliflozin, a potential new treatment that may improve symptoms and reduce heart failure events.GlobeNewswire Inc. · May 14, 2026

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual MeetingLexicon Pharmaceuticals announced results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP), supporting the selection of 10mg as the optimal dose for Phase 3 development. The drug achieved nominally significant reduction in average pain at Week 8 versus placebo with good tolerability. Additional preclinical data on spasticity in multiple sclerosis and spinal cord injury models will also be presented at the American Academy of Neurology Annual Meeting.GlobeNewswire Inc. · Apr 17, 2026

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private PlacementLexicon Pharmaceuticals closed a $94.6 million public offering of 32 million common shares at $1.30 per share and a concurrent private placement of 22.4 million common shares and 367,145 Series B convertible preferred shares at $65 per share on February 2, 2026. The company plans to use net proceeds for research and development of drug candidates and general corporate purposes.GlobeNewswire Inc. · Feb 6, 2026

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private PlacementLexicon Pharmaceuticals closed a $94.6 million public offering of 32 million common shares at $1.30 per share and a concurrent private placement of 22.4 million common shares and 367,145 Series B convertible preferred shares at $65 per share on February 2, 2026. The company intends to use the net proceeds to fund research and development of drug candidates and for general corporate purposes. Underwriters were granted a 30-day option to purchase up to 4.8 million additional shares.Benzinga · Feb 6, 2026

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private PlacementLexicon Pharmaceuticals announced the pricing of a $94.6 million capital raise consisting of a $41.6 million public offering of 32 million common shares at $1.30 per share and a $52.9 million concurrent private placement to Invus affiliate. The offering is expected to close February 2, 2026, with proceeds designated for R&D of drug candidates and general corporate purposes.GlobeNewswire Inc. · Jan 30, 2026

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025A clinical study demonstrated sotagliflozin's potential benefits for heart failure patients with preserved ejection fraction (HFpEF) without diabetes, showing significant improvements in cardiac structure, function, and quality of life.GlobeNewswire Inc. · Nov 8, 2025

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 DiabetesLexicon Pharmaceuticals submitted additional clinical data to the FDA for Zynquista®, an oral SGLT1/SGLT2 inhibitor for type 1 diabetes, following a complete response letter in December 2024. The FDA requires more time to review the data and will provide feedback in Q4 2025.GlobeNewswire Inc. · Sep 22, 2025

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)Lexicon Pharmaceuticals will present patient survey data on diabetic peripheral neuropathic pain (DPNP) at the American Society of Pain and Neuroscience meeting, highlighting their investigational non-opioid treatment pilavapadin.GlobeNewswire Inc. · Jul 18, 2025

to start trading

LX

LXRXLexicon Pharmaceuticals, Inc.

LXRX

Pay with—

Available Balance0.00

Your PositionYou don't own any LXRX yet.

Related Tickers

Earnings